Ustekinumab biosimilars are many and largely sold at big discounts relative to the reference product Stelara. The major PBMs are beginning to publish formularies for 2026. For instance, Express Scripts will have two biosimilars on formulary—Biocon Biologic’s Yesintek and Alvotech/Teva’s Selarsdi (at 90% and 85%, respectively, off the wholesale acquisition cost [WAC] of Stelara) in … Continue reading Fewer Stelara Biosimilar Makers Are Offering High-WAC Pricing